Faron´s financial calendar for 2020

RNS Number : 8985U

Faron Pharmaceuticals Oy

27 November 2019

 

Faron Pharmaceuticals Oy
("Faron" or the "Company")

Faron´s financial calendar for 2020

Company announcement, 27 November 2019 at 6.00 pm (EET)

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN) ("Faron" or the "Company"), the clinical stage biopharmaceutical company, announces the following dates for the Company's financial reporting in 2020:

20 March        Financial Statement release for full year 2019

27 March        Financial Statements for full year 2019

24 September Half-Year Financial Report for the period 1 January - 30 June 2020

The Annual General Meeting is planned for 13 May 2020. A separate stock exchange notice will be issued by Faron´s Board of Directors to convene the meeting.

For more information please contact:

Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
[e-mail]

Panmure Gordon (UK) Limited, Nomad and Broker on AIM
Emma Earl, Freddy Crossley
Phone: [phone]

Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen, Jussi Majamaa
Phone: [phone]

Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: [phone]
Email: [e-mail]

Distribution:
Nasdaq Helsinki Ltd
Key media
www.faron.com

About Faron Pharmaceuticals Oy

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage. Clevegen®, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen® has potential as a single-agent therapy or in combination with other immune checkpoint molecules or other cancer standard cares. Traumakine®, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine®. Faron is based in Turku, Finland. Further information is available at www.faron.com.

 

END

 

 

NORUBVVRKUAAUAA